Greenwich LifeSciences (GLSI) EBITDA (2019 - 2025)
Greenwich LifeSciences (GLSI) posted EBITDA of -$7.9 million for Q4 2025, down 90.32% on a QoQ basis from -$4.2 million in Q3 2025, and up 18.17% year-over-year from -$6.7 million in Q4 2024.
Greenwich LifeSciences (GLSI) EBITDA (2019 - 2025) Analysis & Trends
Greenwich LifeSciences' EBITDA history runs 7 years deep, the most recent figure standing at -$7.9 million for Q4 2025.
- Quarterly EBITDA rose 18.17% year-over-year to -$7.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$19.4 million (down 10.27% YoY) and the FY2025 annual result came in at -$19.4 million, down 10.27% from the prior year.
- EBITDA was -$7.9 million for Q4 2025 at Greenwich LifeSciences, down from -$4.2 million in the prior quarter.
- Across five years, EBITDA topped out at -$600606.0 in Q1 2021 and bottomed at -$9.7 million in Q4 2024.
- A 5-year average of -$3.0 million and a median of -$2.5 million in 2023 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2021 — EBITDA tumbled 258.05% — and 2025, when it increased 18.17%.
- Greenwich LifeSciences' EBITDA stood at -$2.4 million in 2021, then dropped by 21.77% to -$2.9 million in 2022, then gained by 2.03% to -$2.8 million in 2023, then plunged by 242.36% to -$9.7 million in 2024, then gained by 18.17% to -$7.9 million in 2025.
- Business Quant data shows GLSI's EBITDA at -$7.9 million in Q4 2025, -$4.2 million in Q3 2025, and -$4.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Greenwich LifeSciences | 178.53 Mn | 178.53 Mn | - | -7.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.94 Mn |
| Sep 30, 2025 | -4.17 Mn |
| Jun 30, 2025 | -4.05 Mn |
| Mar 31, 2025 | -3.28 Mn |
| Dec 31, 2024 | -9.71 Mn |
| Sep 30, 2024 | -2.73 Mn |
| Jun 30, 2024 | -2.66 Mn |
| Mar 31, 2024 | -2.54 Mn |
| Dec 31, 2023 | -2.84 Mn |
| Sep 30, 2023 | -2.50 Mn |
| Jun 30, 2023 | -1.75 Mn |
| Mar 31, 2023 | -2.24 Mn |
| Dec 31, 2022 | -2.89 Mn |
| Sep 30, 2022 | -2.38 Mn |
| Jun 30, 2022 | -773,307.00 |
| Mar 31, 2022 | -1.99 Mn |
| Dec 31, 2021 | -2.38 Mn |
| Sep 30, 2021 | -866,686.00 |
| Jun 30, 2021 | -753,445.00 |
| Mar 31, 2021 | -600,606.00 |